High-Risk Characteristics for Clinical Failure After Isolated Femoropopliteal Peripheral Vascular Interventions

Abstract

Recent studies suggesting increased late mortality with paclitaxel-coated devices (PCDs) in femoropopliteal peripheral vascular interventions (PVI) prompted the US Food and Drug Administration to recommend limiting the use of PCDs to “patients at particularly high risk for restenosis.” This study's aim is to characterize patients at high risk for restenosis and develop a risk score to guide clinicians in selecting patients for possible treatment with PCDs.